Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia
Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia
复制标题
DOI：
10.1080/10428194.2021.1948027
复制
发表时间：
2021-06-30
影响因子：
2.6
通讯作者：
Huang, Xiao-Jun
中科院分区：
文献类型：
--
作者：
Jiang, Hao;Liu, Xiao-Hong;Huang, Xiao-Jun
为了评估干扰素- α (ifn - α)作为维持治疗在高危急性髓性白血病（AML）患者中的疗效，这项回顾性研究招募了84例高危AML患者：42例接受ifn - α维持治疗，42例未接受ifn - α维持治疗（对照组）。ifn - α治疗的中位随访时间和持续时间分别为26（6-54）个月和18（2-24）个月。最后一次巩固化疗后的4年估计无复发生存率（RFS）， ifn - α组为86.8%(95%可信区间（CI）， 75.8-97.8%)，对照组为55.7% (95% CI, 37.2-74.3%) （p=.007）。ifn - α组和对照组的4年估计总生存率分别为94.4% （95% CI, 868 -102%）和76.4% (95% CI, 61.9-90.9%) （p= 0.040）。Cox回归分析显示，ifn - α治疗是影响RFS的唯一独立因素（p= 0.004）。ifn - α维持治疗可预防巩固化疗后有利风险AML复发。
To evaluate the efficacy of interferon-alpha (IFN-alpha) as maintenance therapy in patients with favorable-risk acute myeloid leukemia (AML), this retrospective study enrolled 84 patients with favorable-risk AML: 42 patients who received IFN-alpha maintenance therapy and 42 patients who did not (control). The median follow-up time and duration of IFN-alpha treatment was 26 (6-54) months and 18 (2-24) months, respectively. The 4-year estimated relapse-free survival (RFS) after the last consolidation chemotherapy was 86.8% (95% confidence interval (CI), 75.8-97.8%) in the IFN-alpha group and 55.7% (95% CI, 37.2-74.3%) in the control group (p=.007). The 4-year estimated overall survival was 94.4% (95% CI, 86.8-102%) and 76.4% (95% CI, 61.9-90.9%) in IFN-alpha and control groups, respectively (p=.040). The Cox regression analysis showed that IFN-alpha treatment was the only independent factor affecting RFS (p=.004). Maintenance therapy with IFN-alpha may prevent relapse in favorable-risk AML after consolidation chemotherapy.